- Millendo Therapeutics (NASDAQ:MLND) announces dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301.
- The first-in-human trial is designed to evaluate the safety and tolerability of MLE-301.
- MLE-301 is a reversible antagonist of the human neurokinin 3 receptor or NK3R in development for the treatment of vasomotor symptoms associated with menopause.
- “We are pleased to advance MLE-301 into clinical development, prioritizing our resources on this valuable asset and leveraging Millendo’s expertise in the NK3R category," said Julia C. Owens, President and CEO.
- Press Release
Millendo launches early-stage study of lead drug
Recommended For You
More Trending News
About TPST Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
TPST | - | - |
Tempest Therapeutics, Inc. |